Canine Autoimmune Diagnosis via TNIP3 SNP Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating autoimmune diseases in dogs, such as hypothyroidism, are inadequate, leading to delayed detection and potential irreversible tissue damage, as they rely on incomplete diagnostic tests and lack specific genetic markers or early treatment options.
Innovation Solution
Identifying dogs at risk through single nucleotide polymorphism (SNP) testing, particularly at the TNIP3 gene locus on chromosome 19, and administering an effective amount of tea extract to regulate immune function and reduce inflammation, which can be incorporated into a palatable and nutritionally complete canine diet.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic tests (single T4 level) are used, then the diagnostic process is simple and quick, but the diagnosis accuracy is insufficient leading to delayed detection
Solution Approach 1:
The patent segments the diagnostic process into multiple independent testing components: SNP genotyping assay, full thyroid panel test (measuring free T4, total T3, total T4), and autoantibody assays. This segmentation allows each test to target specific aspects of hypothyroidism detection, improving overall diagnostic accuracy while maintaining manageable complexity through modular testing protocols
Solution Approach 2:
The patent implements preliminary genetic screening using SNP testing at the TNIP3 locus before clinical symptoms fully develop. By performing this preliminary genetic assessment, the system identifies at-risk dogs early in the disease progression, enabling intervention before irreversible tissue damage occurs, thus improving diagnostic precision without requiring complex advanced imaging or invasive procedures
2Loss of time
If genetic markers are used for early identification, then early detection capability is improved, but the testing complexity and cost increase
Solution Approach 1:
The patent extracts and focuses on a specific genetic marker (TNIP3 locus SNP) that has been identified as strongly associated with autoimmune thyroiditis in dogs. By concentrating on this single high-value genetic marker rather than performing whole-genome sequencing or testing multiple low-value markers, the system achieves early detection capability with relatively simple and cost-effective SNP genotyping assays
Solution Approach 2:
The patent employs disposable SNP genotyping assays and standard laboratory reagents that are inexpensive and widely available. These single-use testing components enable early genetic screening without requiring expensive specialized equipment or complex infrastructure, making early detection accessible while minimizing testing complexity
3Reliability
If treatment is delayed until clinical symptoms appear, then treatment cost is reduced, but irreversible tissue damage occurs
Solution Approach 1:
The patent implements preliminary genetic screening to identify dogs with high-risk genotypes (specific SNP combinations at the TNIP3 locus) before clinical hypothyroidism develops. This preliminary identification enables proactive monitoring and early intervention with thyroid hormone supplementation or immunosuppressive therapy, preventing irreversible thyroid tissue destruction and maintaining treatment effectiveness with lower medication dosages
4Measurement precision
If comprehensive thyroid panel tests are performed, then diagnostic accuracy is improved, but the time and resources required increase
Solution Approach 1:
The patent uses preliminary SNP genetic testing as a rapid first-line screen to identify dogs at high risk for autoimmune thyroiditis. Only dogs with high-risk genotypes proceed to the comprehensive thyroid panel test (measuring free T4, total T3, total T4, and autoantibodies). This staged approach maintains high diagnostic accuracy for at-risk animals while improving overall diagnostic efficiency by avoiding unnecessary comprehensive testing in low-risk population
Solution Approach 2:
The patent applies different levels of diagnostic intensity to different risk groups based on genetic findings. High-risk dogs (with specific SNP combinations) receive comprehensive thyroid panel testing and close monitoring, while low-risk dogs receive standard care. This localized quality adjustment optimizes resource allocation while maintaining diagnostic accuracy where it matters most
Data Source
AI summary
The disclosure includes methods of identifying a dog at risk of developing a an autoimmune disease or condition, for example a hypothyroid disease or condition, comprising testing whether the dog exhibits one or more selected single nucleotide polymorphisms (SNPs), together with diagnostic kits for carrying out such methods, methods of treatment or prophylaxis of such autoimmune disease or condition, e.g., comprising administering an effective amount of tea extract to a dog in need thereof, and a canine diet or supplement comprising tea extract, useful for treatment of prophylaxis of such autoimmune disease or condition, or for maintenance of thyroid health in a dog.